Cat lymphoma and pet insurance: months of remission, policy years, and the clauses between them

Cornell's three outcomes in months

Cornell's Feline Health Center page on lymphoma, last updated 2021, draws on Margaret McEntee, DVM, a professor of oncology at Cornell's College of Veterinary Medicine. It calls lymphoma the most frequently diagnosed of all feline cancers and says it is now "most often seen in the gastrointestinal tract," where the disease can be "very different in terms of treatment and prognosis" than elsewhere. Three treatment paths on the page carry numbers, and each one is, before it is anything else, a length of time.

These are three different quantities. The over-90-percent figure is a share of cats reaching remission, the 50 to 80 percent figure is a share with a duration attached, and the two-to-four-year figure is survival, which is not remission at all. A policy question needs a fourth number, the months of invoices a diagnosis generates, and the page does not give it directly. Remission durations are averages across cats, so some cats fall well on either side of them, and Cornell notes that prognosis "can vary depending on the exact location and type of lymphoma present."

Age adds a second clock. Cornell says cats of any age can develop lymphoma, "although most affected animals are 10 to 12 years of age," which is where the enrollment limits in the age limits guide start to matter. A cat enrolled at seven has several clean years of record to build before that range; a cat enrolled at eleven is already inside it.

Months become policy years

A policy is sold by the term, so the useful translation runs from months to terms. The table counts how many 12-month policy terms a course of that length touches when it starts anywhere inside a term. A four-month course that begins in month ten touches two terms; the same course beginning in month one touches one.

What repeats depends on the form. Figo's dog sample is explicit: "When the Treatment dates of an Illness or Injury fall into two or more Policy periods, You will be required to pay a Policy Annual Deductible for each Policy period." Spot's deductible "applies during each policy period," and MetLife's "will apply once per Policy Period." Trupanion's 08/11 form works the other way: "Once the deductible amount has been met for a specific condition, the policy will pay out all future losses for that condition at the selected co-insurance rate."

A quiet stretch has a price of its own on the annual forms. Figo and MetLife both reduce the deductible by $50 for each claim-free renewal, and both say that when a claim is paid the deductible returns to its original amount for the next term. A remission of four to nine months can carry a cat through a renewal with few invoices, but the earlier claim has already reset the credit. The deductible, reimbursement and limits decoder sets out how each of those levers works before a cancer claim tests it.

VS-21: $300 a treatment, $1,200 in all

Start with what the VS-21 (02-17) Superior Plan sample prints. Its schedule is headed "Effective 4-07. Subject to change," and its footnote reads: "Chemotherapy/radiation treatment(s) may be eligible for coverage at a rate of $300 per treatment up to a maximum of $1200. Proof of malignancy required." Column D is "the benefit allowance limit for Chemotherapy and Radiation treatment as it relates to the Primary Diagnosis," and an asterisk marks it on neoplasia rows, including code 3103 Lymphosarcoma: Column A $528, Column B $200 for diagnostic testing, Column C $100 for anesthesia, Column D $300 up to $1,200, and Column E $370 for the condition when it is treated as a secondary diagnosis.

Set that beside Cornell's schedule for aggressive protocols, intravenous and "often once weekly for many weeks." At $300 a treatment the allowance is spent after four treatments, since 4 times $300 is $1,200, and every weekly dose after the fourth earns nothing from Column D. Cornell gives no number of weeks, only "many."

Three gaps in the form decide how far that goes. It does not define a treatment, so a weekly infusion, a clinic visit and a day of oral medication are not distinguished, which matters most on the small cell path of daily tablets. It does not say whether the $1,200 is per incident or per policy term. And section 4.B says the company will "pay 90% of covered veterinary services expenses up to a maximum of 90% of the Benefit Schedule diagnostic code that applies to your pet's condition, less your deductible," without saying whether Column D sits inside that. If it does, the figures become $270 a treatment and $1,080; if it does not, they are $300 and $1,200. Column A, meanwhile, is described as covering "exam, injections, hospitalization, treatment, surgery," so an insurer could place a weekly injection in Column A's $528 instead of Column D, and the form does not settle that either.

The 90 percent columns assume the rate reaches every column, the open question above. The specialist column comes from section 4.D: when the primary veterinarian refers the cat to a specialist, "you will receive a second Benefit Schedule allowance for your pet's treatment by the specialist. This additional allowance applies once per incident and does not increase your policy's maximum benefit per incident or the maximum benefit for each policy term." That fits Cornell's picture of a veterinary oncologist choosing the protocol, though the form defines a specialist as "a diplomate of a specialty board recognized by the American Veterinary Medical Association," and whether a given oncologist qualifies is for the insurer to confirm. The maximums are $4,500 per incident and $14,000 per policy term (section 4.C). Within Columns A to D, both specialist figures in the table, $3,650.40 and $4,348.80, stay under $4,500. The Specialized Diagnostic Tests list sits outside those columns, adds up to $1,000 per incident, and could lift either figure past the incident cap.

The filing row moves the ceiling. Row 1246 totals $2,416 across Columns A to D against $2,028 for row 3103, a difference of $388. The form says each condition "is eligible for payment under only one primary diagnostic code and any applicable secondary diagnostic code, per incident," and its rows are named Lymphosarcoma and Neoplasia, Small intestine-Surgical, with none named for intestinal lymphoma. Which row the insurer picks for an intestinal lymphoma treated with drugs is a real variable.

The last gap is the one a multi-year course meets. The form counts "Chronic or ongoing conditions" as "one incident no matter how many times you consult a veterinarian" and applies the deductible "once to each incident during the policy term." A lymphoma that runs three years may therefore be one incident with one $528 primary allowance, or three incidents, depending on whether a renewal opens a new one. The form is silent, and this is the first question to ask about it. The footnote's "Proof of malignancy required" means a pathology report; Cornell says a definitive diagnosis of intestinal lymphoma "requires biopsies of the intestinal tract."

VS-G-3-CA: allowances that reset each term

The VS-G-3-CA (02-15) Major Medical form, a California edition, is built the other way round. Section 4.B makes its diagnosis allowances "the most that we will pay during the policy term for any condition covered by this policy, regardless of the number of incidents or treatments during the policy term," and section 5 says the deductible "applies to each policy term." A multi-year lymphoma meets a fresh allowance and a fresh deductible every term, the reverse of the uncertainty in VS-21.

If the insurer files the lymphoma under 3103 and counts row 7100 as the secondary allowance, one term's ceiling is $1,475 plus $2,400, which is $3,875. Filed under 4005 it is $860 plus $2,400, or $3,260, which is $615 less. The form says each incident draws on "only one Column A Primary Diagnosis Allowance and any applicable Column B Secondary Diagnosis Allowance," and it does not say whether two Column B lines, such as 7100 and 7001, can both apply, so these are single-B figures.

The form defines chemotherapy as "treatment through chemicals primarily designed to stop the progression of cancer." Cornell calls chlorambucil an "oral chemotherapy drug" and prednisolone a steroid. Whether either home-dispensed path is a row 7100 treatment, or simply prescribed medication inside the primary allowance, is a reading to put to the insurer; the form does not state it.

Section 4.D also reaches back to the work-up, paying diagnostic testing only when it results in the diagnosis of a covered condition, so a lymphoma found to predate the policy takes the tests that found it down with it.

Which schedule row a lymphoma lands on

Cornell lists where lymphoma turns up: the gut, the peripheral and internal lymph nodes, "the chest cavity (mediastinal lymphoma), the liver, spleen, kidneys, nasal cavity, eyes or central nervous systems." The two schedules have no row named for lymphoma at any of those sites except the lymph node rows, so the nearest named neoplasia row has to stand in. The table pairs each site with that row in both schedules.

All nine VS-21 rows in the table carry the Column D chemotherapy and radiation allowance, and Cornell adds that radiation therapy "can be very effective in the treatment of lymphoma in the nasal cavity," which is the other half of that column's wording. The two forms name their rows differently. VS-21 labels six of the nine rows Surgical, two Medical and one (lymphosarcoma) neither, while VS-G-3-CA prints a Medical row with a Column A allowance for eight of the nine sites (its lymph node row is unlabelled). A cat treated with drugs rather than surgery sits more naturally on a Medical row, so the form that prints one for most sites leaves less room for argument about whether a surgical row applies.

Cancer wording in seven other documents

The seven remaining documents carry no schedule, so cancer becomes a wording question. The nine documents compared here are the VS-21 (02-17) and VS-G-3-CA (02-15) forms, the Figo dog sample IAIC FPI POL 0320 (08/01/2023), the AKC North Carolina sample IAIC PPI AI POL 007 NC 0421, the Spot Arizona sample PET-P-20000-1024, the MetLife Ohio sample PET21-01-V, Trupanion form TRU-00001 (08/11), the Pets Best booklet APIC-PBI0001-ILL (12/2015) and the PetPartners CompanionPlus terms PPI-CPLUS-TC-004 (04/2014). Several are older editions, and all are sample or filed forms rather than any insurer's current policy for a given cat.

None of the seven documents prints a dollar cap or a waiting period named for cancer, or uses the word lymphoma. They fall into two groups. Figo, Spot and AKC name cancer or chemotherapy as covered, and Figo adds a cancer-specific pre-existing rule. Trupanion, MetLife, Pets Best and PetPartners say nothing about it, which is not an exclusion: each covers illness and treatment generally, so the general clauses on pre-existing conditions, medical necessity and limits carry the claim. The Pets Best booklet splits the two paths Cornell describes: intravenous chemotherapy given in a clinic sits in the underlying coverage, while the oral drugs of the small cell and steroid-only paths are home medication, which needs the Take Home Prescription Medications supplement chosen at enrollment and a drug on the formulary the booklet says is posted on its website.

Figo's exclusion 1(a) is the sharpest of these, and narrower than it first looks. It applies only to a cat diagnosed or treated for cancer before the waiting period ends, and for that cat it reaches every later manifestation, not only the first. A cat whose lymphoma is diagnosed after the wait falls under the ordinary rules. The dog-side version of the same mechanics, with per-incident caps and a six-month invoice timeline, is in the dog cancer claim guide.

Remission measured against the word cured

Remission is Cornell's word, and only one of the nine documents uses it. Cornell reports "remission of their clinical signs" for the small cell group and remission "for an average duration of between four and nine months" for aggressive protocols, so remission is a state that ends. The Pets Best booklet names it in order to count it against the owner: its definition T treats a condition as Present when it shows observable signs, "including those conditions in remission or controlled by medication, whether or not the Condition is noted in your Pet's medical records."

The other documents define the opposite state, cured, where they define it at all, and the definitions set the bar high. VS-21 requires "resolution of a condition so that ongoing or intermittent treatment is not required and recurrences or complications are not expected." VS-G-3-CA requires the pet to be "fully restored to normal health without any treatment or management." Figo and Spot require freedom from "symptoms" and treatment. Cornell describes small cell lymphoma as treated at home with "regular monitoring," and gives aggressive-protocol remissions an average length. On those words a cat in remission on maintenance medication is not cured, and a cat off treatment still has to show that recurrence is not expected, which an average remission of four to nine months puts in question. That is a reading of the words, not a ruling by any insurer. AKC, MetLife, Trupanion and PetPartners define no cured state at all.

The gap matters in two places. One is a cat switching insurers in remission, where the new form judges the earlier diagnosis under its own pre-existing and cured language; the guide to switching pet insurance records what restarts, and the guide to insuring after a diagnosis covers a first policy bought once the word lymphoma is already in the chart. The other is a cat staying put, where VS-21 section 8.B excludes "the conditions listed on the Declarations Page or Renewal Certificate of your policy" and VS-G-3-CA section 13 allows removal only for a condition "cured at least six months before" the request, with "Chronic conditions are not eligible for removal." The cat IBD and chronic vomiting guide lays ten chronic and cured wordings side by side. The feline diabetes guide follows the same word through a disease where remission is a recognized outcome: a remission is a clinical fact, and a cure is a contract term.

Weight loss, a mass, and the first-sign date

Cornell lists the signs of intestinal lymphoma as "weight loss, vomiting, diarrhea, and often either a decreased or increased appetite." It adds that "Physical exam findings may be normal, though thickened intestines or abdominal masses may be felt," and that bloodwork "is likely to be normal." A disease that opens with ordinary signs leaves a trail of ordinary chart notes, and every look-back clause reads those notes. The sentence that follows in Cornell's text, that the signs and test results "are often indistinguishable from cats with Inflammatory Bowel Disease," is why that question has its own page, the cat IBD and chronic vomiting guide.

Two of Cornell's findings meet specific clauses. The first is the abdominal mass. Figo's exclusion 1(c) is a mass clause: "If a Pet had Undiagnosed masses prior to the end of the Waiting Period, any mass, or condition where a mass is a Clinical Sign, is not covered, including those caused by cancer. If the cause of the mass that occurred prior to the end of the Waiting Period can be diagnostically narrowed down via cytology, unrelated conditions may be covered." A mass felt at an exam inside the waiting period therefore closes the door on every condition in which a mass is a sign, lymphoma among them, unless cytology narrows the cause to something unrelated.

The second is weight, the most datable of the signs. A cat that lost weight between two annual exams before enrollment has a first sign on the chart whether or not anyone called it one, and a chart with steady weights on both sides of the start date does not. None of that is a reason to skip an exam. Cornell recommends twice-yearly physical examinations "that include blood chemistry testing and thorough palpation" for cats seven and older, and those exam notes are the evidence the clauses read. How far back each form looks (18 months at Trupanion and Pets Best, 12 months for a non-chronic illness at Figo, no stated limit at several others) is compared in the pre-existing conditions decoder.

Where FeLV enters the lymphoma record

Cornell says the chest-cavity (mediastinal) and spread-throughout (multicentric) forms "are closely linked to infection with the feline leukemia virus (FeLV) and, to a lesser extent, the feline immunodeficiency virus (FIV)." It adds that these viruses "are less frequently seen today, presumably due to testing and isolation of infected cats and the use of vaccines that protect against FeLV," and that "Unvaccinated outdoor cats are at greater risk than indoor cats due to their greater exposure to FeLV infection."

ABCD's FeLV guideline (updated March 27, 2025 and reviewed November 19, 2025) puts numbers on the link: "Approximately 25% of cats with progressive FeLV infection will develop lymphoma, with FeLV-infected cats being about 60 times more likely to develop lymphoma compared to non-infected cats." It calls mediastinal lymphoma the most commonly observed FeLV-associated form. It also draws the limit that matters for the gut: "alimentary and extranodal lymphomas only rarely seem to be associated with FeLV infection," and "the role of FeLV in the pathogenesis of lymphoma has diminished in recent years, especially in regions with low FeLV prevalence."

The two bodies label the vaccine differently. ABCD, a European panel, says FeLV vaccination "is classified as non-core but is recommended for cats at risk of exposure," and that "No FeLV vaccine offers complete protection or prevents infection entirely." Cornell's FeLV page, which prints "Updated 2024," calls it "now considered a core vaccine for kittens" and says it "will not protect 100% of cats vaccinated." None of the nine policy documents uses the words core or non-core. That is the useful fact: the clauses key to a veterinarian's recommendation, a veterinarian's protocol, or whether a vaccine is available, so the label is beside the point and the chart is not.

The FIV-positive cat guide sets FeLV and FIV beside each other and tabulates the same vaccine clauses against a positive antibody test. The lymphoma question is a different one, because it runs through the cause of the tumor rather than through a test result.

Vaccine clauses against the vaccine record

Seven of the nine documents carry a clause that can remove an illness a vaccine might have prevented. They key to different things, and the table gives each clause with its exception, because the exception is where the chart does its work. Spot and MetLife print no vaccine clause.

None of those clauses mentions lymphoma. Each reaches a lymphoma claim only through FeLV, by one of two routes. Either the lymphoma is itself "related to" an illness the vaccine would have prevented, which is Figo's wording, or the cat's FeLV infection is excluded and the lymphoma is treated as its complication. The complication clauses are VS-21 exclusion T ("tests or treatments for complications of conditions excluded or limited by this policy"), VS-G-3-CA exclusion V ("any complication or progression of any condition excluded by this policy"), Pets Best section 9.C item 7 ("Complications of or diagnostic tests, treatments, therapies, and/or medications related to Conditions not covered or restricted by this policy"), PetPartners 5.e ("secondary complications from such excluded illness, injury, or service") and MetLife's "complications of conditions or procedures that are not otherwise covered by this Policy."

So the chain has links, and the chart supplies them. An FeLV infection has to be documented, there has to be no vaccine on the record and none declined on veterinary advice, and the lymphoma has to be tied to the infection. A chart without a positive FeLV result breaks the first link, and ABCD's "only rarely" for alimentary lymphoma weakens the third for the gut form, which is the form Cornell calls most common. The mediastinal and multicentric forms, where Cornell and ABCD both describe a closer link, are the ones where an insurer has something to point to.

The records that answer these clauses are ordinary ones. A dated vaccination certificate shows the doses and when they were given; ABCD's primary course for an at-risk kitten is a first dose at eight or nine weeks and a second at twelve, with a booster a year later. A dated FeLV test result shows status, and ABCD advises testing before vaccinating unless infection is very unlikely. A veterinary note recommending against the vaccine answers the exceptions in Pets Best, PetPartners and the two Nationwide forms, and ABCD itself advises "avoiding unnecessary FeLV vaccination (e.g., in indoor-only or already immune cats)." A note that an owner declined a recommended dose is what Figo's exclusion 18 turns on. Whether to vaccinate belongs to the owner and a veterinarian; these are readings of clauses, not advice about a cat.

Four starting points, four things to ask

Four situations, each paired with the clause that decides it and the question to put to an insurer in writing. The care itself stays with the owner and a veterinarian.

If the diagnosis is confirmed and the cat is uninsured, start with the guide to insuring after a diagnosis. The cats section lists the other multi-year claims.